WHEELING -- A pharmaceutical corporation is suing over claims another company has infringed upon its dementia drug patent.
Novartis Pharmaceuticals Corporation, Novartis Corporation, Novartis AG, Novartis Pharma AG and LTS Lohmann Therapie-Systeme AG filed a lawsuit June 20 in the U.S. District Court West Virginia Northern against Mylan Inc. and Mylan Pharmaceuticals Inc., citing patent infringement.
According to the complaint, Novartis Pharmaceuticals Corporation's Exelon Patch, for the treatment of dementia, was approved by the FDA in 2007 and 2012 for several doses. The lawsuit also states Novartis and LTS hold patents regarding the composition of the drug, the main ingredient of which is rivastigmine.
According to the suit, Mylan has submitted to the FDA a new drug application for the commercial manufacture and sale of a rivastigmine transdermal system, which the plaintiffs claim infringes upon their patent.
Novartis and LTS are seeking judgment that Mylan has infringed upon their patents and an order restraining Mylan from manufacturing and selling their drug.
Novartis and LTS are being represented in the case by attorneys James F. Companion and Yolonda G. Lambert of Schrader Byrd & Companion PLLC in Wheeling.
U.S. District Court West Virginia Northern Case No. 1:14-cv-00106-IMK
Mylan accused of infringing upon dementia drug patent
ORGANIZATIONS IN THIS STORY